Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2024 → 2025: -100.00%
Price change 2025 → 2026: -99.19%
Price change 2026 (year to date): -99.24%
Financial growth
Revenue CAGR (6 years): -28.45%
Earnings CAGR (6 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.35
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio not available.
Correction (6 months)
Current correction: 99.74% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="WOK" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| WORK Medical Technology Group Ltd. | – | 0.35 | −28.4 % | 🔒 |
| Spineway S.A. | – | 0.07 | +9.3 % | – |
| CompuMed, Inc. | – | 0.23 | +10.2 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Daré Bioscience, Inc. | – | 0.93 | +9.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by WORK Medical Technology Group Ltd. Class A over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 52.5 m | 1.2 m | 2.2 % | n/a |
| 2021 | 45.9 m | 6.0 m | 13.0 % | -12.7 % |
| 2022 | 19.7 m | 865,210 | 4.4 % | -57.0 % |
| 2023 | 13.6 m | 112,030 | 0.8 % | -31.2 % |
| 2024 | 11.5 m | -3.5 m | -30.4 % | -15.2 % |
| 2025 | 9.8 m | -1.1 m | -10.9 % | -14.4 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by WORK Medical Technology Group Ltd. Class A over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 508,708 | 731,178 | 1.6 m | 6.6 m | 4.1 m |
| Total Debt | 6.6 m | 6.3 m | 9.1 m | 13.5 m | 6.4 m |
| Net Debt | 6.1 m | 5.6 m | 7.5 m | 6.9 m | 2.4 m |
| Equity | 10.0 m | 10.0 m | 9.9 m | 13.2 m | 18.3 m |
| Total assets | 30.7 m | 25.5 m | 30.0 m | 36.3 m | 33.2 m |
| Operating cash flow | -7.2 m | -2.3 m | 2.2 m | -2.2 m | 6.2 m |
| Investments (capex) | 60,000 | 2.0 m | 455,391 | 9.2 m | 1.3 m |
| Free cash-flow | -7.2 m | -4.3 m | 1.6 m | -11.5 m | 4.9 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.
Valuation and competitors
WORK Medical Technology Group Ltd. Class A compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| WORK Medical Technology Group Ltd. Class A | 2.9 m | n/a | -10.9 % |
| Lipella Pharmaceuticals Inc. LIPO | 2,773 | n/a | n/a |
| Silexion Therapeutics Ltd. SLXN | 52,296 | n/a | 0.0 % |
| Indaptus Therapeutics, Inc. INDP | 359 m | n/a | 0.0 % |
| Protagenic Therapeutics, Inc. PTIX | 832,696 | n/a | 0.0 % |
| SciSparc Ltd. SPRC | 205,142 | n/a | -1,422.8 % |
| Mobile-health Network Solutions Class A Ordinary Shares MNDR | 23,256 | n/a | -44.2 % |
| Artelo Biosciences, Inc. ARTL | 7.2 m | n/a | 0.0 % |
| Jasper Therapeutics, Inc. JSPR | 15.2 m | n/a | 0.0 % |
| Sector median (Nasdaq) | 20.8 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
WORK Medical Technology Group Ltd. Class A: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Stock splits
| Date | Operation |
|---|---|
| 18/06/2026 | reverse split: 1 share for 100 |
| 29/12/2025 | reverse split: 1 share for 100 |
| 21/10/2025 | reverse split: 1 share for 100 |
Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in WORK Medical Technology Group Ltd. Class A.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about WORK Medical Technology Group Ltd. Class A
What is the WORK Medical Technology Group Ltd. Class A share price?
Latest recorded price: 1.20 USD on 13/11/2026, for a market cap of 2.9 m USD.
What is the revenue of WORK Medical Technology Group Ltd. Class A?
9.8 m USD for fiscal year 2025, with net income of -1.1 m USD (net margin -10.9 %).
Is WORK Medical Technology Group Ltd. Class A stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN KYG9767H1092).
How many employees does WORK Medical Technology Group Ltd. Class A have?
216 full-time employees according to the latest published profile.
Who runs WORK Medical Technology Group Ltd. Class A?
Shuang Wu is the company's chief executive.